Latest filing published 23 Feb 2022 for Theravance Biopharma, Inc., €231k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Kenneth R. Pitzer: trading record in brief
Kenneth R. Pitzer, listed as senior executive, appears in our data through filings on Theravance Biopharma, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 15 March 2016 to 18 February 2022, the count stands at 34 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 23 February 2022 with a share grant (€231k) in Theravance Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Kenneth R. Pitzer
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 27,299 shares@ US$9.610.028% mcap44.1% of flowOrdinary SharesSEC:0001415889-22-001701:0
- 52,000 shares0Ordinary SharesSEC:0001415889-22-001184:0
- 4,310 shares@ US$8.368.4% of flowOrdinary SharesSEC:0001415889-21-005469:0
- 4,307 shares@ US$14.0513.7% of flowOrdinary SharesSEC:0001179110-21-008398:0
- 4,310 shares@ US$17.8016.6% of flowOrdinary SharesSEC:0001179110-21-005846:0
5 of 5 declarations
